Anlon Healthcare Limited Q2 FY26 earnings call summary

NSE: AHCL · BSE: 544497

Earnings call of 19 Nov 2025, summarised by AI from the filing.

Anlon Healthcare Q2 FY26 total income ₹52.32 cr (+116% YoY) and PAT ₹9.32 cr; guides next year revenue ₹360-400 cr after inorganic acquisition.

Growth driver CDMO commercialization with two global innovators scheduled for Q3 FY27; three molecules in validation.
Risk Capacity constraint may lead to loss of business if expansion or acquisition is delayed.

Anlon Healthcare Limited Q1 FY27 results

As filed: Revenue ₹31.0 cr (−6% year on year), EBITDA ₹7.5 cr (+24% year on year), PAT ₹4.8 cr (+20% year on year), EBITDA margin 24.1% (+590 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Q4 FY26: Revenue ₹55.4 cr, EBITDA ₹13.9 cr, PAT ₹9.8 cr, EBITDA margin 25.1%. Not scored. No result for the same quarter last year. Share price after the results: +14.3% in 27 days (Nifty 500: +0.6%).
Q3 FY26: Revenue ₹35.6 cr, EBITDA ₹12.3 cr, PAT ₹5.2 cr, EBITDA margin 34.7%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 30 days (Nifty 500: −6.9%).
Q2 FY26: Revenue ₹52.0 cr, EBITDA ₹13.0 cr, PAT ₹9.0 cr, EBITDA margin 25.0%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 30 days (Nifty 500: −0.2%).
Q1 FY26: Revenue ₹33.0 cr, EBITDA ₹6.0 cr, PAT ₹4.0 cr, EBITDA margin 18.2%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Q1 FY27: Earnings call (6 Aug 2026), Results deck (5 Aug 2026), Results press release (31 Jul 2026)
Q4 FY26: Earnings call (3 Jun 2026), Results deck (3 Jun 2026), Results press release (29 May 2026)
Q3 FY26: Earnings call (19 Feb 2026), Results deck (19 Feb 2026)
Q2 FY26: Earnings call (19 Nov 2025), Results deck (19 Nov 2025)

Figures from the company's filings with NSE and BSE. Not investment advice.